Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a
once-daily dose, in elderly patients with acute myelogenous leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Kinex Pharmaceuticals Inc Kinex Pharmaceuticals Inc.